NCCN Guidelines
Multiple Myeloma
Guidelines
-
NCCN Guidelines Version 3.2024
- Active (symptomatic) Myeloma
- Multiple Myeloma
- Smoldering (asymptomatic) Myeloma
- Solitary Plasmacytoma
Guidelines for Patients
-
Multiple Myeloma-English Version 2023
-
Multiple Myeloma-Chinese Version 2023
-
Multiple Myeloma-French Version 2023
-
Multiple Myeloma-Korean Version 2022
-
Multiple Myeloma-Spanish - Latin America Version 2023
Educational Events and Programs
Continuing Education
-
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
-
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
-
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification
-
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma
-
Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care
International
Translations
-
Arabic Version 5.2022
-
Chinese Version 5.2022
-
French Version 5.2022
-
German Version 5.2022
-
Italian Version 5.2022
-
Japanese Version 5.2022
-
Korean Version 5.2022
-
Polish Version 1.2023
-
Portuguese (Latin America) Version 3.2023
-
Romanian Version 1.2023
-
Russian Version 1.2023
-
Spanish (European Editions) Version 5.2022
-
Spanish (Latin America) Version 3.2023
-
Ukrainian Version 3.2023
Harmonized
-
English (Africa) Version 3.2023